OPUS GENETICS
Opus Genetics is a patient-first, science-driven gene therapy company tackling manufacturing obstacles standing in the way of treatments for ultra-rare blinding conditions.
OPUS GENETICS
Industry:
Health Care Health Diagnostics Wellness
Founded:
2004-01-01
Address:
Raleigh, North Carolina, United States
Country:
United States
Website Url:
http://www.opusgtx.com
Status:
Active
Contact:
919-525-9820
Total Funding:
19 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Global Site Tag Sitelinks Search Box Yoast WordPress SEO Plugin
Similar Organizations
AppliedVR
AppliedVR offers virtual reality-based therapeutic treatments that address the complexity of chronic pain.
Careship
Careship helps families find the right caregiver for their loved ones.
CorSanitas
CorSanitas is a healthcare company that assists its members as they reverse their heart disease and any accompanying conditions.
DaoCloud
DaoCloud is the largest national network of vetted wellness practitioners.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
GOJO Industries
GOJO Industries is a company that offers health skin and hygiene solutions.
Gravity Diagnostics
Gravity Diagnostics is a full-service state-of-the-art CLIA laboratory licensed in all 50 states providing innovative laboratory testing.
HealthPoint Plus
HealthPoint Plus is disrupting the way patients access primary care with subscription-based medicine.
Immunostics
Immunostics offers a broad portfolio of diagnostics solutions.
InFuse Holdings
InFuse Holdings operates high-quality, cost-effective ambulatory infusion centers.
Kikoko
Kikoko is a cannabis botanical wellness company for women.
LivWell Enlightened Health
LivWell Enlightened Health is a medical cannabis company producing and retailing multi-state cannabis.
Lyme Diagnostics Ltd.
Lyme Diagnostics offers reliable, standard diagnostic system for diagnosing Lyme borreliosis.
MeetMindful
MeetMindful is a dating site platform for people who are into health, well-being, and mindfulness.
Monument
Monument is an alcohol addiction treatment platform for those looking to change their relationship with alcohol.
Native American Connections (NAC)
Native American Connections (NAC) is an innovative multi-service organization working to improve community health and wellness
NICE Recovery Systems
NICE Recovery Systems is a provider of therapy device to improve the convenience and efficacy of cold plus compression therapy.
Oppimi
Oppimi creates therapeutic tools for diagnosing and treating learning disabilities using a video-game approach.
OPUS
At-home wellness tech for emotional fitness
Quit Genius
Quit Genius is a digital clinic for treating nicotine, alcohol, and opioid addictions.
Seven Starling
Seven Starling is a digital clinic uniquely focused on treating perinatal mental health conditions.
Squatty Potty
An American personal care company
Sunniva
Sunniva is a vertically integrated medical company.
Two Chairs
Two Chairs is a behavioral health company that operates a mental health therapy platform to offer in-person psychotherapy.
Upside Health
At Upside Health, weโre transforming the way chronic pain is assessed and treated.
Vision Healthcare
Vision Healthcare is a consumer healthcare company active in different European countries.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Wallflowr
Wallflowr mission is to empower Networks to become resources for professional wellness for their growing communities.
Current Advisors List
Current Employees Featured
Founder
Investors List
Bios Partners
Bios Partners investment in Seed Round - Opus Genetics
Retinal Degeneration Fund
Retinal Degeneration Fund investment in Seed Round - Opus Genetics
Manning Family Foundation
Manning Family Foundation investment in Seed Round - Opus Genetics
Key Employee Changes
Official Site Inspections
http://www.opusgtx.com Semrush global rank: 5.62 M Semrush visits lastest month: 1.51 K
- Host name: 172.67.177.251
- IP address: 172.67.177.251
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
![](/img/wait.gif)
More informations about "Opus Genetics"
Company Information :: Opus Genetics, Inc. (IRD) - ir.opusgtx.com
Investor Relations. LifeSci Advisors 250 West 55th Street, Suite 3401 New York, NY 10019 T: 646-889-1200 [email protected]See details»
Company Overview - Opus Genetics
Combined company advancing first-in-class retinal gene therapies. Ocuphire Pharma, Inc. and Opus Genetics have combined under the Opus Genetics name, and as a combined company, we are committed to building an innovative, โฆSee details»
Corporate Governance :: Opus Genetics, Inc. (IRD) - ir.opusgtx.com
Committee List; Board Members Audit Compensation Nominating & Corporate Governance; Cam Gallagher, M.B.A.See details»
Opus Genetics - LinkedIn
Ocuphire Pharma, Inc. and Opus Genetics have combined under the Opus Genetics name (Nasdaq: IRD). As a combined company, we are committed to building an innovative, efficient and sustainable ...See details»
Opus Genetics - Crunchbase Company Profile & Funding
Opus Genetics is a patient-first, science-driven gene therapy company tackling manufacturing obstacles standing in the way of treatments for ultra-rare blinding conditions.See details»
George Magrath, MD, MBA, MS - Opus Genetics - opusgtx.com
Most recently, Dr. Magrath was CEO of Lexitas Pharma Services, a leading contract research organization in ophthalmology. Lexitas experienced a substantial growth in headcount, โฆSee details»
Opus Genetics - VentureRadar
"Opus Genetics is a groundbreaking gene therapy company for inherited retinal diseases with a unique model and purpose. Our AAV-based gene therapy portfolio, based on the work of โฆSee details»
Opus Genetics Announces Financial Results for Third Quarter 2024 โฆ
Nov 12, 2024 For more information, please visit www.opusgtx.com. Forward Looking Statements. This press release contains forward-looking statements within the meaning of the โฆSee details»
Opus Genetics Leadership to Present at 3rd Annual Gene
Sep 12, 2022 RESEARCH TRIANGLE PARK, N.C., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-first gene therapy company developing treatments for inherited โฆSee details»
Opus Genetics, Inc. (IRD)
Nov 12, 2024 The company is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to โฆSee details»
Terms of Use - Opus Genetics
Oct 18, 2024 Opus Genetics Website Terms of Use Last Modified: October 18, 2024 Acceptance of the Terms of Use These terms of use are entered into by ...See details»
Financial Results :: Opus Genetics, Inc. (IRD) - ir.opusgtx.com
Jun 30, 2024 Fiscal Year Ended Dec 31, 2023. Earnings Release HTML. 10-K HTML XBRL ZipSee details»
Opus Genetics, Inc. /OLD/ (Opus Genetics, Inc. /OLD/) - ่ฏ็ฉ็ฎก็บฟ_ โฆ
The resulting company will operate under the name Opus Genetics and the Nasdaq ticker symbol (IRD) RALEIGH, N.C., Oct. 25, 2024 /PRNewswire/ -- The RD Fund (Retinal Degeneration โฆSee details»
Ocuphire Pharma Announces Acquisition of Opus Genetics
Oct 22, 2024 Back to OpusGTX.com ; Press Releases. Ocuphire Pharma Announces Acquisition of Opus Genetics. October 22, 2024 4:05 pm EDT Download as PDF Acquisition โฆSee details»
Associate Director/Director Quality Manufacturing - opusgtx.com
Opus Genetics 223 South West Street, Suite 900 Raleigh NC 27603 opusgtx.com Associate Director/Director Quality Manufacturing About Opus This is an exciting opportunity to join โฆSee details»
First Patient Dosed With LCA5 Gene Therapy - CGTliveโข
Sep 19, 2023 Opus Genetics has dosed the first patient with Leber congenital amaurosis resulting from biallelic mutations in the LCA5 gene (LCA5) with the gene therapy OPGx-LCA5 โฆSee details»
Patients & Families - Opus Genetics - opusgtx.com
Why gene therapy? Genetic mutations prevent production and/or appropriate function of the protein encoded by the gene. Opus Genetics is developing gene therapies to deliver a normal โฆSee details»
Press Releases :: Opus Genetics, Inc. (IRD) - ir.opusgtx.com
Aug 8, 2024 Back to OpusGTX.com ; Press Releases. Year. Release Type. Nov 12, 2024 8:00 am EST. Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides โฆSee details»
IRD Programs - Opus Genetics - opusgtx.com
OPGx-LCA5 . LCA5 is an early-onset retinal degeneration that affects approximately 200 people in the U.S. Evidence of a structural-functional dissociation in such individuals suggests an โฆSee details»